LISBON, PORTUGAL — 05 April 2017
Global biotherapeutics leader CSL Behring today announced it is presenting efficacy data in intravenous Alpha1-Proteinase Inhibitor (A1-PI) therapy at the 3rd International Research Conference on Alpha-1 Antitrypsin and the 6th Alpha -1 Global Patient Congress. CSL Behring is a sponsor of these annual conferences.
Dr. Alan Altraja, Head of Clinic, Professor of Pulmonology, University of Tartu, Estonia, will present the RAPID OLE trial.
“RAPID is a landmark study that provides evidence for the disease-modifying effect of A1-PI therapy on the progression of emphysema in patients with severe Alpha-1 Antitrypsin Deficiency (AATD). With RAPID OLE results, we confirmed the value of early intervention,” says Dr. Altraja, who will present the data on 7 April.
At CSL Behring we are proud of our ongoing commitment to patients with rare and serious diseases, which includes the AATD patient community,” adds Lutz Bonacker, Senior Vice President Europe, CSL Behring. “Through clinical studies like RAPID, we continue to deliver on our promise to advance our understanding of disorders such as AATD, and ultimately, to improve patient care and treatment outcomes.”
The International Research Conference and the Global Patient Congress are being organized by Alpha-1 Global, a program of the Alpha-1 Foundation that is dedicated to building a collaborative network of patient leaders, physicians and researchers around the world. This year’s conference will bring together more than 200 participants from 26 countries.
About the RAPID Study
The RAPID study enrolled 180 severely deficient alpha-1 patients in the U.S. and Europe who were treated for 2 years with Respreeza® or Placebo. The study, published in Lancet in June 2015, showed a significant reduction in the rate of lung tissue loss as measured by CT scan lung density. In those patients who continued into the extension study, where all subjects received Respreeza®, the benefit was maintained for another 2 years.
About Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency is an inherited condition that can result in severe lung disease in adults and liver disease at any age, as well as other less known manifestations such as panniculitis, a skin disease. AATD is the most commonly known genetic risk factor for emphysema and is commonly referred to as genetic COPD. Low levels or absence of the protective protein alpha-1 antitrypsin, which is produced by the liver, characterize AATD.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs nearly 20,000 people, delivering its life-saving therapies to people in more than 60 countries. For more information visit www.cslbehring.com and follow us on www.Twitter.com/CSLBehring.
Office: +1 610 878 4802
Mobile: +1 610 306 9355